Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Rigosertib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib
    Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib

    28 Sep 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/09/28/2751138/0/en/Onconova-Therapeutics-to-Present-a-Late-Breaking-Abstract-on-Rigosertib-at-the-2023-EADV-Congress.html

    GLOBENEWSWIRE
    28 Sep 2023
    Share Share
    Onconova Announces Dosing of First Participant in Phase 2 Trial of Rigosertib
    Onconova Announces Dosing of First Participant in Phase 2 Trial of Rigosertib

    25 May 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/05/25/2676053/0/en/Onconova-Therapeutics-Announces-Dosing-of-First-Participant-in-Investigator-Sponsored-Phase-2-Trial-of-Rigosertib-Plus-Pembrolizumab-in-Metastatic-Melanoma-Patients-Refractory-to-I.html

    GLOBENEWSWIRE
    25 May 2023
    Share Share
    Onconova Presents Data Characterizing Rigosertib Mechanisms of Action
    Onconova Presents Data Characterizing Rigosertib Mechanisms of Action

    07 Mar 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/03/07/2622028/0/en/Onconova-Therapeutics-Presents-Preclinical-Data-Characterizing-Rigosertib-s-Mechanisms-of-Action-at-the-AACR-Targeting-RAS-Conference.html

    GLOBENEWSWIRE
    07 Mar 2023
    Share Share
    Onconova Announces Updated Data from Investigator-sponsored Ph 1/2a Rigosertib
    Onconova Announces Updated Data from Investigator-sponsored Ph 1/2a Rigosertib

    12 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/12/2514021/0/en/Onconova-Therapeutics-Announces-Updated-Data-from-Investigator-sponsored-Phase-1-2a-Trial-Evaluating-Rigosertib-in-Combination-with-Nivolumab-in-Advanced-KRAS-mutated-Non-Small-Cel.html

    GLOBENEWSWIRE
    12 Sep 2022
    Share Share
    Onconova Announces Encouraging Clinical Data on Rigosertib-Nivolumab Combination
    Onconova Announces Encouraging Clinical Data on Rigosertib-Nivolumab Combination

    22 Sep 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/09/22/2301282/0/en/Onconova-Therapeutics-Announces-Encouraging-Clinical-Data-Supporting-the-Anti-Cancer-Activity-of-Rigosertib-Nivolumab-Combination-in-Advanced-KRAS-Non-Small-Cell-Lung-Cancer.html

    GLOBENEWSWIRE
    22 Sep 2021
    Share Share
    Onconova Submits Application For Rigosertib To Participate In Federally Funded
    Onconova Submits Application For Rigosertib To Participate In Federally Funded

    27 Jul 2020

    // PRESS RELEASE

    https://investor.onconova.com/news-releases/news-release-details/onconova-therapeutics-submits-application-rigosertib-participate

    PRESS RELEASE
    27 Jul 2020
    Share Share